Abstract:Background: Metformin is a first-line drug for treating type 2 diabetes and has gained considerable interest as a potential anticancer agent. Increasing evidence suggests that metformin antagonizes diabetes and tumors through disrupting metabolic homeostasis and altering energy state. However, whether AMP activated protein kinase (AMPK) contributes to such effects of metformin remains controversial. Methods: We performed integrative metabolomics analyses to systematically examine the effects of metformin on metabolic pathways in Prkaa1 wild type (WT) and knock-out (KO) mouse embryonic fibroblast (MEF) cells as well as human cells based on gas chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry (CE-MS). Results: Metformin treatment induced metabolic reprogramming and reduced the energy state of both Prkaa1 WT and KO MEF cells, as evidenced by suppressed tricarboxylic acid (TCA) cycle, elevated lactate production as well as decreased NAD+/NADH ratio. Additionally, metabolic flux analysis also showed that metformin Ampkα-independently increased metabolic flux from glucose to lactate and decreased metabolic flux from acetyl-CoA to TCA cycle as well as from pyruvate to malate. Moreover, metformin Ampkα-dependently upregulated P-Acc but Ampkα-independently inhibited the levels of P-mTor, P-S6, Lc3, Atgl and P-Erk in MEF cells. Similarly, we demonstrated that a commonly used AMPK agonist 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) and fetal bovine serum (FBS) starvation, as a common model for energy stress, both led to Ampkα-independent metabolism alterations in MEF cells. Furthermore, these effects of metformin were also confirmed in human hepatocellular carcinoma (HCC) cells as well as in MCF10A shControl and shPRKAA1 cells. Importantly, we found that metformin could obviously inhibit colony conformation of HCC cells in an Ampkα-independent manner. Conclusions: Our data highlight a comprehensive view of metabolic reprogramming mediated by metformin as well as AICAR. These observations suggest that metformin could affect cellular metabolism largely bypassing Ampkα, and may provide a new insight for its clinical usage.

Metformin Plays a Dual Role in MIN6 Pancreatic β Cell Function through AMPK-dependent Autophagy

Metformin may protect beta-cell function and insulin secretion capacity by relieving glucotoxicity and lipotoxicity

Metformin‐induced autophagy and irisin improves INS‐1 cell function and survival in high‐glucose environment via AMPK/SIRT1/PGC‐1α signal pathway

Metformin Attenuates Palmitic Acid-Induced Insulin Resistance In L6 Cells Through The Amp-Activated Protein Kinase/Sterol Regulatory Element-Binding Protein-1c Pathway

Low-dose metformin targets the lysosomal AMPK pathway through PEN2

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

Metformin Activates AMPK and Inhibits Insulin Secretion in MIN6 Cell Line Culture

Metformin inhibits MAPK signaling and rescues pancreatic aquaporin 7 expression to induce insulin secretion in type 2 diabetes mellitus

Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity

The Improvement of Pancreatic β-cell Function of Glucose Intolerant KKAy Mice after Metformin Treatment and the Possible Mechanisms

Metformin attenuates high glucose-induced injury in islet microvascular endothelial cells

The effects of metformin on autophagy

Metformin Protects Endothelial Function in Diet-Induced Obese Mice by Inhibition of Endoplasmic Reticulum Stress Through 5′ Adenosine Monophosphate–Activated Protein Kinase–Peroxisome Proliferator–Activated Receptor Δ Pathway

Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice

Metformin Preserves Insulin Secretion in Pancreatic Β-Cells Through FGF21/Akt Pathway in Vitro and in Vivo.

Metformin Activates AMPK Through the Lysosomal Pathway

New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway

Metformin and MiR-365 Synergistically Promote the Apoptosis of Gastric Cancer Cells Via MiR-365-PTEN-AMPK Axis.

Effect of metformin on proliferation and apoptosis in human pancreatic cancer cell line CFPAC-1

Metformin Induces Renal Medullary Interstitial Cell Apoptosis in Type 2 Diabetic Mice

Metformin protects cardiomyocytes against oxygen-glucose deprivation injury by promoting autophagic flux through AMPK pathway